產(chǎn)品描述: | Lirametostat (CPI-1205)是具有口服生物活性的選擇性組蛋白賴氨酸甲基轉(zhuǎn)移酶EZH2的抑制劑,對(duì)EZH2和EZH1的IC50分別為2 nM和52 nM。它具有潛在的抗腫瘤活性 |
靶點(diǎn): |
EZH2(Cell-free assay):2 nM ; EZH1(Cell-free assay):52 nM;HistoneMethyltransferase |
體外研究: |
在多發(fā)性骨髓瘤和漿細(xì)胞瘤細(xì)胞模型中,EZH2抑制劑CPI-1205的處理能夠?qū)е录?xì)胞凋亡 |
體內(nèi)研究: |
在體內(nèi)實(shí)驗(yàn)中,CPI-1205具有極好的口服生物利用度。在重復(fù)給藥的過(guò)程中,動(dòng)物對(duì)CPI-1205具有良好的耐受性,沒(méi)有明顯地體重減少。在大鼠和狗中,CPI-1205具有比較高的血液清除率(大鼠-3.19 L/h/kg、狗-1.41 L/h/kg)。在這兩個(gè)物種中,都有比較好的口服利用度,分別為44.6%和46.2%。在毒性檢測(cè)中,其耐受良好,在恢復(fù)期間,毒性作用是具有可逆性的 |
動(dòng)物實(shí)驗(yàn): |
Animal Models: CB-17 SCID小鼠 Dosages: 160 mg/kg orally twice daily Administration: 口服 |
參考文獻(xiàn): |
1. Vaswani RG, et al. Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas. J Med Chem. 2016. 2. Shilpi Arora, et al. EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics. Blood. 2016, 128:5672. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.928 ml |
9.642 ml |
19.284 ml |
5 mM |
0.386 ml |
1.928 ml |
3.857 ml |
10 mM |
0.193 ml |
0.964 ml |
1.928 ml |
50 mM |
0.039 ml |
0.193 ml |
0.386 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |